News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ariad Pharmaceuticals, Inc. (ARIA) Announces Support of Patients With Resistant or Intolerant CML Through Its Donation to Chronic Disease Fund


4/2/2013 10:04:21 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it had made a donation to the Chronic Disease Fund (CDF) in support of patients with chronic myeloid leukemia (CML) who are resistant or intolerant to prior therapy. CDF is an independent non-profit charitable organization that helps eligible patients with chronic diseases, cancer and other life-altering conditions obtain the life-saving medications they need. Through ARIAD’s contribution, the organization will provide financial assistance to eligible patients with resistant or intolerant CML who require help paying their out-of-pocket expenses, including co-pays or co-insurance. CDF will determine the distribution of these funds and patient eligibility.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES